In addition, metformin has been reported to inhibit epithelial–mesenchymal transition (EMT), inhibit IGF signaling, and selectively suppress cancer stem-like cell (CSC) differentiation [100,101,102,103,104]. This evidence concerns the gene IGF1 and cancer.